1. Home
  2. ENTA vs GNE Comparison

ENTA vs GNE Comparison

Compare ENTA & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

N/A

Current Price

$12.12

Market Cap

374.6M

Sector

Health Care

ML Signal

N/A

Logo Genie Energy Ltd. Class B Stock

GNE

Genie Energy Ltd. Class B Stock

N/A

Current Price

$13.82

Market Cap

382.1M

Sector

Utilities

ML Signal

N/A

Company Overview

Basic Information
Metric
ENTA
GNE
Founded
1995
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Power Generation
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
374.6M
382.1M
IPO Year
2012
2011

Fundamental Metrics

Financial Performance
Metric
ENTA
GNE
Price
$12.12
$13.82
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$20.40
N/A
AVG Volume (30 Days)
147.1K
45.1K
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
2.18%
EPS Growth
29.93
N/A
EPS
N/A
0.76
Revenue
$102,814,000.00
$425,202,000.00
Revenue This Year
$7.76
$17.49
Revenue Next Year
N/A
$7.07
P/E Ratio
N/A
$18.13
Revenue Growth
16.48
N/A
52 Week Low
$4.09
$13.27
52 Week High
$17.15
$28.47

Technical Indicators

Market Signals
Indicator
ENTA
GNE
Relative Strength Index (RSI) 39.11 45.84
Support Level $12.09 $13.56
Resistance Level $15.52 $14.87
Average True Range (ATR) 0.63 0.62
MACD -0.17 -0.06
Stochastic Oscillator 7.62 30.00

Price Performance

Historical Comparison
ENTA
GNE

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About GNE Genie Energy Ltd. Class B Stock

Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.

Share on Social Networks: